Published in AAPS J on July 24, 2014
Incorporating Stage-Specific Drug Action into Pharmacological Modeling of Antimalarial Drug Treatment. Antimicrob Agents Chemother (2016) 0.78
Mathematical Modelling to Guide Drug Development for Malaria Elimination. Trends Parasitol (2016) 0.75
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet (2012) 17.62
Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet (2012) 11.82
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis (2012) 6.94
Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol (1993) 4.98
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother (2000) 4.77
Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med (2005) 4.65
Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A (2010) 4.50
The parasite clearance curve. Malar J (2011) 4.30
Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis (2010) 3.59
Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg (2001) 3.46
Parallel tempering: theory, applications, and new perspectives. Phys Chem Chem Phys (2005) 3.39
Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am J Trop Med Hyg (1999) 2.94
Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci U S A (2008) 2.80
Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology (2002) 2.67
Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev (1984) 2.65
Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother (2000) 2.54
Development of a highly sensitive genus-specific quantitative reverse transcriptase real-time PCR assay for detection and quantitation of plasmodium by amplifying RNA and DNA of the 18S rRNA genes. J Clin Microbiol (2011) 2.44
Antimalarial dosing regimens and drug resistance. Trends Parasitol (2008) 2.40
Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther (1999) 2.16
Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther (2012) 1.87
Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc Natl Acad Sci U S A (2013) 1.83
P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PLoS One (2012) 1.80
Estimating sequestered parasite population dynamics in cerebral malaria. Proc Natl Acad Sci U S A (1998) 1.64
Models in biology: 'accurate descriptions of our pathetic thinking'. BMC Biol (2014) 1.59
The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J Theor Biol (1998) 1.55
Stage specific actions of antimalarial drugs on Plasmodium falciparum in culture. Am J Trop Med Hyg (1989) 1.51
Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of 'dormancy', a partial cytostatic effect of the drug, and its implication for treatment regimens. Parasitology (2000) 1.50
A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS One (2011) 1.47
Mathematical model of the first wave of Plasmodium falciparum asexual parasitemia in non-immune and vaccinated individuals. Am J Trop Med Hyg (2006) 1.40
Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol (2002) 1.38
Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J Pharmacokinet Pharmacodyn (2007) 1.34
Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. Clin Infect Dis (2012) 1.29
Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Antimicrob Agents Chemother (2010) 1.27
A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead. BMC Public Health (2011) 1.27
Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob Agents Chemother (2013) 1.21
Pharmacokinetic-pharmacodynamic modelling of the antimalarial activity of mefloquine. Parasitology (2001) 1.18
Modelling the chloroquine chemotherapy of falciparum malaria: the value of spacing a split dose. Parasitology (1998) 1.15
MCMC can detect nonidentifiable models. Biophys J (2012) 1.15
Mathematical modelling of malaria chemotherapy: combining artesunate and mefloquine. Parasitology (2002) 1.13
Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malar J (2012) 1.11
Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin. Br J Clin Pharmacol (2005) 1.09
A framework for assessing the risk of resistance for anti-malarials in development. Malar J (2012) 1.09
Probability of emergence of antimalarial resistance in different stages of the parasite life cycle. Evol Appl (2009) 1.09
Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure. Antimicrob Agents Chemother (2011) 1.04
Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria. Malar J (2011) 1.02
A model for estimating total parasite load in falciparum malaria patients. J Theor Biol (2002) 1.02
Improving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugs. PLoS Comput Biol (2013) 1.00
Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria. Malar J (2012) 0.99
Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling. Malar J (2014) 0.92
Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria. Antimicrob Agents Chemother (2012) 0.92
A robust design for identification of the Parasite Clearance Estimator. Malar J (2013) 0.87
Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen. Clin Pharmacol Ther (2013) 0.86
Effect of mature blood-stage Plasmodium parasite sequestration on pathogen biomass in mathematical and in vivo models of malaria. Infect Immun (2013) 0.82
Bayesian age-stage modelling of Plasmodium falciparum sequestered parasite loads in severe malaria patients. Parasitology (2004) 0.82
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med (2008) 6.61
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One (2009) 5.81
A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis (2012) 5.24
The pathophysiology of vivax malaria. Trends Parasitol (2009) 4.57
In vivo parasitological measures of artemisinin susceptibility. J Infect Dis (2010) 4.25
Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med (2007) 3.13
Artemisinin combination therapy for vivax malaria. Lancet Infect Dis (2010) 3.08
Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation. J Infect Dis (2007) 3.02
Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis (2008) 3.01
Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci U S A (2008) 2.80
Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One (2007) 2.66
A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J (2009) 2.64
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis (2011) 2.16
Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis (2009) 2.15
Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol (2012) 1.95
Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. J Infect Dis (2009) 1.86
Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc Natl Acad Sci U S A (2013) 1.83
The anaemia of Plasmodium vivax malaria. Malar J (2012) 1.82
Simplified antimalarial therapeutic monitoring: using the day-7 drug level? Trends Parasitol (2008) 1.70
Inferred relatedness and heritability in malaria parasites. Proc Biol Sci (2010) 1.69
Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity. Malar J (2008) 1.69
A biological model for influenza transmission: pandemic planning implications of asymptomatic infection and immunity. PLoS One (2007) 1.64
Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis (2011) 1.64
Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J (2012) 1.61
Understanding influenza transmission, immunity and pandemic threats. Influenza Other Respir Viruses (2009) 1.60
Plasmodium vivax trophozoites insensitive to chloroquine. Malar J (2008) 1.54
A simple score to predict the outcome of severe malaria in adults. Clin Infect Dis (2010) 1.54
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51
Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. J Infect Dis (2006) 1.49
The global public health significance of Plasmodium vivax. Adv Parasitol (2012) 1.46
Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog (2009) 1.46
High deformability of Plasmodium vivax-infected red blood cells under microfluidic conditions. J Infect Dis (2009) 1.40
Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. PLoS Pathog (2010) 1.37
Comparison of three molecular methods for the detection and speciation of Plasmodium vivax and Plasmodium falciparum. Malar J (2007) 1.35
Considerations on the use of nucleic acid-based amplification for malaria parasite detection. Malar J (2011) 1.32
Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J Virol (2010) 1.31
Influenza: accounting for prior immunity. Science (2009) 1.28
Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses. J Infect Dis (2008) 1.28
Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations. J Infect Dis (2008) 1.26
Coma associated with microscopy-diagnosed Plasmodium vivax: a prospective study in Papua, Indonesia. PLoS Negl Trop Dis (2011) 1.23
Antigenic drift of the pandemic 2009 A(H1N1) influenza virus in A ferret model. PLoS Pathog (2013) 1.20
L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial. PLoS One (2013) 1.20
Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria. Am J Trop Med Hyg (2007) 1.20
Impaired skeletal muscle microvascular function and increased skeletal muscle oxygen consumption in severe falciparum malaria. J Infect Dis (2012) 1.15
Lung injury in uncomplicated and severe falciparum malaria: a longitudinal study in papua, Indonesia. J Infect Dis (2005) 1.14
Prior immunity helps to explain wave-like behaviour of pandemic influenza in 1918-9. BMC Infect Dis (2010) 1.14
Early parasitological response following artemisinin-containing regimens: a critical review of the literature. Malar J (2013) 1.14
Greater endothelial activation, Weibel-Palade body release and host inflammatory response to Plasmodium vivax, compared with Plasmodium falciparum: a prospective study in Papua, Indonesia. J Infect Dis (2010) 1.11
Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malar J (2012) 1.11
Improving case definitions for severe malaria. PLoS Med (2007) 1.09
Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax. Antimicrob Agents Chemother (2012) 1.09
Diagnosis and treatment of Plasmodium vivax malaria. Adv Parasitol (2012) 1.05
Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax. J Infect Dis (2013) 1.03
A randomized pilot study of L-arginine infusion in severe falciparum malaria: preliminary safety, efficacy and pharmacokinetics. PLoS One (2013) 1.02
Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria. Malar J (2014) 1.01
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax. Antimicrob Agents Chemother (2010) 0.99
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med (2015) 0.99
Effective preparation of Plasmodium vivax field isolates for high-throughput whole genome sequencing. PLoS One (2013) 0.98
The burden and treatment of HIV in tuberculosis patients in Papua Province, Indonesia: a prospective observational study. BMC Infect Dis (2010) 0.98
Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria. Adv Parasitol (2012) 0.97
Improving the availability of artesunate for treatment of severe malaria. Med J Aust (2006) 0.96
Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax. Antimicrob Agents Chemother (2011) 0.96
Diagnosis and antiviral intervention strategies for mitigating an influenza epidemic. PLoS One (2011) 0.94
Potential of artemisinin-based combination therapies to block malaria transmission. J Infect Dis (2013) 0.92
Safety profile of L-arginine infusion in moderately severe falciparum malaria. PLoS One (2008) 0.92
Antimalarial therapies in children from Papua New Guinea. N Engl J Med (2009) 0.92
Artemisinin combination therapy for malaria: beyond good efficacy. Clin Infect Dis (2009) 0.92
Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. Malar J (2015) 0.91
Virus detection and its association with symptoms during influenza-like illness in a sample of healthy adults enrolled in a randomised controlled vaccine trial. Influenza Other Respir Viruses (2012) 0.90
Reducing uncertainty in within-host parameter estimates of influenza infection by measuring both infectious and total viral load. PLoS One (2013) 0.90
Modelling strategic use of the national antiviral stockpile during the CONTAIN and SUSTAIN phases of an Australian pandemic influenza response. Aust N Z J Public Health (2010) 0.89
An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing. PLoS Negl Trop Dis (2012) 0.89
Genetic diversity and population structure of Plasmodium vivax in Central China. Malar J (2014) 0.89
A robust design for identification of the Parasite Clearance Estimator. Malar J (2013) 0.87
Hospitalisation with infection, asthma and allergy in Kawasaki disease patients and their families: genealogical analysis using linked population data. PLoS One (2011) 0.86
Towards optimal design of anti-malarial pharmacokinetic studies. Malar J (2009) 0.85
Understanding mortality in the 1918-1919 influenza pandemic in England and Wales. Influenza Other Respir Viruses (2010) 0.85
The effect of varying analytical methods on estimates of anti-malarial clinical efficacy. Malar J (2009) 0.84
Influence of contact definitions in assessment of the relative importance of social settings in disease transmission risk. PLoS One (2012) 0.84
Childhood wheeze phenotypes show less than expected growth in FEV1 across adolescence. Am J Respir Crit Care Med (2014) 0.83
Nonlinear mixed-effects modelling of in vitro drug susceptibility and molecular correlates of multidrug resistant Plasmodium falciparum. PLoS One (2013) 0.83
Impaired pulmonary nitric oxide bioavailability in pulmonary tuberculosis: association with disease severity and delayed mycobacterial clearance with treatment. J Infect Dis (2013) 0.83
Age-related susceptibility to severe malaria associated with galectin-2 in highland Papuans. J Infect Dis (2010) 0.82
Trends in malaria research in 11 Asian Pacific countries: an analysis of peer-reviewed publications over two decades. Malar J (2011) 0.82
Severe congenital malaria acquired in utero. Am J Trop Med Hyg (2010) 0.82
A study of the TNF/LTA/LTB locus and susceptibility to severe malaria in highland papuan children and adults. Malar J (2010) 0.81
Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challenges. Br J Clin Pharmacol (2015) 0.79
Human T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase (HGXPRT) in acute malaria. Malar J (2009) 0.79
Increased carboxyhemoglobin in adult falciparum malaria is associated with disease severity and mortality. J Infect Dis (2013) 0.79
Maximising the public health benefit of antimalarials. Lancet Infect Dis (2010) 0.79
Application of a case-control study design to investigate genotypic signatures of HIV-1 transmission. Retrovirology (2012) 0.78
Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature (2016) 0.77
Pertussis models to inform vaccine policy. Hum Vaccin Immunother (2015) 0.77
Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine. Emerg Infect Dis (2017) 0.75
Advances in Parasitology. Preface. Adv Parasitol (2012) 0.75
The epidemiology of Plasmodium vivax. Preface. Adv Parasitol (2013) 0.75